integra lifesciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. integra's orthopedic products include devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. integra is a leader in neurosurgery, offering a broad portfolio of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. in the united states, integra is a leading provider of surgical instruments to hospitals, surgery centers and alternate care sites, including physician and dental offices. founded in 1989 integra is headquartered in plainsboro, new jersey and has over 3,500 employees worldwide. integra's common stock is li
Company profile
Ticker
IART
Exchange
Website
CEO
Peter Arduini
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INTEGRA LIFESCIENCES CORP
SEC CIK
Corporate docs
Subsidiaries
ACell, Inc. • Arkis Biosciences Inc. • Ascension Orthopedics Limited • BIMECO, Inc. • BioD, LLC • BioDlogics, LLC • BioRecovery, LLC • CardioDyne, Inc. • Cathtec Incorporated • Caveangle Limited ...
IRS number
510317849
IART stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
25 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
8-K
Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
28 Feb 24
8-K/A
Departure of Directors or Certain Officers
27 Feb 24
8-K
Entry into a Material Definitive Agreement
20 Dec 23
8-K
Departure of Directors or Certain Officers
13 Dec 23
8-K
Entry into a Material Definitive Agreement
13 Dec 23
10-Q
2023 Q3
Quarterly report
25 Oct 23
8-K
Integra LifeSciences Reports Third Quarter 2023 Financial Results
25 Oct 23
Transcripts
IART
Earnings call transcript
2023 Q4
28 Feb 24
IART
Earnings call transcript
2023 Q3
25 Oct 23
IART
Earnings call transcript
2023 Q2
27 Jul 23
IART
Earnings call transcript
2023 Q1
26 Apr 23
IART
Earnings call transcript
2022 Q4
22 Feb 23
IART
Earnings call transcript
2022 Q3
26 Oct 22
IART
Earnings call transcript
2022 Q2
27 Jul 22
IART
Earnings call transcript
2022 Q1
27 Apr 22
IART
Earnings call transcript
2021 Q4
23 Feb 22
IART
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
4
Witte Jan De
13 Mar 24
4
ROBERT T. JR. DAVIS
13 Mar 24
4
Michael J. McBreen
13 Mar 24
4
Eric Schwartz
13 Mar 24
4
Chantal Veillon-Berteloot
13 Mar 24
4
Lea Daniels Knight
13 Mar 24
4
Harvinder Singh
13 Mar 24
4
Jeffrey Mosebrook
13 Mar 24
4
ROBERT T. JR. DAVIS
12 Mar 24
4
Michael J. McBreen
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 273.73 mm | 273.73 mm | 273.73 mm | 273.73 mm | 273.73 mm | 273.73 mm |
Cash burn (monthly) | 11.82 mm | 19.85 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 70.70 mm | 118.73 mm | n/a | n/a | n/a | n/a |
Cash remaining | 203.03 mm | 155.00 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 17.2 | 7.8 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 257 |
Opened positions | 34 |
Closed positions | 55 |
Increased positions | 81 |
Reduced positions | 112 |
13F shares | Current |
---|---|
Total value | 2.59 tn |
Total shares | 88.47 mm |
Total puts | 73.30 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Richard E Caruso | 11.98 mm | $540.41 mm |
Tru St Partnership | 8.52 mm | $0.00 |
Vanguard | 7.16 mm | $273.43 bn |
BLK Blackrock | 6.83 mm | $261.00 bn |
MS Morgan Stanley | 5.95 mm | $227.18 bn |
Capital Research Global Investors | 3.07 mm | $117.18 bn |
Wellington Management | 3.03 mm | $115.87 bn |
Alliancebernstein | 2.79 mm | $106.66 bn |
Clearbridge Advisors | 2.74 mm | $104.71 bn |
Cooke & Bieler | 2.71 mm | $103.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Davis Robert T. JR. | Common Stock | Payment of exercise | Dispose F | No | No | 35.88 | 1,581 | 56.73 k | 65,107 |
12 Mar 24 | Davis Robert T. JR. | Common Stock | Payment of exercise | Dispose F | No | No | 35.88 | 443 | 15.89 k | 66,688 |
12 Mar 24 | Michael J. McBreen | Common Stock | Payment of exercise | Dispose F | No | No | 35.88 | 440 | 15.79 k | 57,882 |
12 Mar 24 | Michael J. McBreen | Common Stock | Payment of exercise | Dispose F | No | No | 35.88 | 1,572 | 56.40 k | 58,322 |
12 Mar 24 | Eric Schwartz | Common Stock | Payment of exercise | Dispose F | No | No | 35.88 | 348 | 12.49 k | 63,581 |
12 Mar 24 | Eric Schwartz | Common Stock | Payment of exercise | Dispose F | No | No | 35.88 | 1,090 | 39.11 k | 63,929 |
11 Mar 24 | Witte Jan De | Common Stock | Payment of exercise | Dispose F | No | No | 36.22 | 205 | 7.43 k | 18,350 |
11 Mar 24 | Witte Jan De | Common Stock | Option exercise | Acquire M | No | No | 0 | 205 | 0.00 | 18,555 |
11 Mar 24 | Witte Jan De | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 205 | 0.00 | 130,280 |
11 Mar 24 | Witte Jan De | RSU Common Stock | Grant | Acquire A | No | No | 0 | 41,414 | 0.00 | 130,485 |
News
Integra LifeSciences Launches MicroMatrix Flex To Provide Convenient Access To Hard-To-Reach Areas In Complex Cases
11 Mar 24
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
7 Mar 24
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $41
1 Mar 24
Analyst Scoreboard: 5 Ratings For Integra Lifesciences
29 Feb 24
JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $49
29 Feb 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Integra Lifesciences Holdings Corp - IART
27 Mar 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Integra Lifesciences Holdings Corp - IART
25 Mar 24
Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases
11 Mar 24
Integra LifeSciences Announces Leadership Transition Plan
28 Feb 24
Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
28 Feb 24